Sulanemadlin
InvestigationalFirst-in-class stapled alpha-helical peptide and dual MDM2/MDMX inhibitor that reactivates wild-type p53 tumor suppressor function. Phase 1/2 trials demonstrated 59% disease control rate with notably low hematologic toxicity compared to MDM2-only inhibitors. Novel chemoprotection application being developed for retinoblastoma with Advancium Biosciences partnership.
ALRN-6924 · MP-4897
18 human studies
- Preclinical
- 36%
- Clinical
- 64%
Based on 28 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 47: best human evidence is a single uncontrolled open-label Phase 1 (Saleh 34301750, n=71, 1A=15) plus a first-in-pediatric Phase 1 (42189874, n=22); the only RCT (chemoprotection) failed, so best-study RoB is high (1B=6). Total human N ~100-300 (1C=6); evidence is direct in population/route/outcome (1D=12); substantial multi-model preclinical program (1E=8). Mechanism 96: MDM2/MDMX target with nM binding, functional p53 activation (MIC-1 biomarker), and TP53-WT-vs-mutant selectivity acting as genetic-context validation (2A=40); full target->p21/PUMA/BAX pathway mapped (2B=28); monotonic dose-response across xenografts + human PD (2C=18); confirmed in vivo (2D=10). Plausibility 80: mechanism->surrogate established, surrogate->clinical-benefit inferred but not RCT-proven (3A=26); fully coherent with p53 biology (3B=23); multiple same-class MDM2 inhibitors reproduce the effect (3C=18); tightly scoped claim (3D=13). Global Coverage 68: replicated by independent academic groups (Dana-Farber, MD Anderson, Miami, Peking, IIT Bombay) beyond originating Aileron (4A=24) across many countries (4B=22), ~20-100 studies (4C=17), investigational/FDA-registered only (4D=5). Community Experience 9: clinical-trial-only investigational oncology agent with negligible real-world community use. Effectiveness clinical (low confidence): Phase 1 59% disease control rate but low objective-response (~10% ORR, mostly stable disease) and a failed chemoprotection RCT, with no head-to-head comparator data.
Sulanemadlin reactivates the p53 tumor suppressor pathway by blocking its negative regulators MDM2 and MDMX.
How It Works (Simplified)
Sulanemadlin acts as a “decoy” that frees p53 to resume its cancer-fighting function:
Binds to MDM2 and MDMX proteins that normally suppress p53, freeing p53 to activate tumor suppressor genes.
Unlike small molecule MDM2 inhibitors, blocks BOTH MDM2 and MDMX simultaneously, preventing resistance escape.
Activated p53 triggers apoptosis in cancer cells through PUMA, BAX, and NOXA gene expression.
In normal cells, p53 activation causes temporary G1 arrest, allowing them to “hide” during chemotherapy exposure.
Key Research: Saleh MN et al. (USA, 2021) demonstrated a 59% disease control rate with low hematologic toxicity in a first-in-human Phase 1 trial. PMID:34301750
Important Limitations
- Requires TP53 wild-type status; ineffective in TP53-mutant tumors
- Currently investigational with no regulatory approvals
- Administered IV only; oral formulation not available
- Long-term safety data limited to Phase 1/2 trial durations
Administered by intravenous infusion on a weekly or twice-weekly schedule. Rapid p53 pathway activation confirmed by serum MIC-1 elevation, a pharmacodynamic biomarker. Dose-dependent pharmacokinetic and pharmacodynamic response observed.
PMID:34301750Disease stabilization may become apparent. Tumor marker changes and imaging assessment typically at cycle 2. In the separately investigated chemoprotection setting, low doses transiently arrest the cell cycle in healthy tissues; clinical benefit was not confirmed in a randomized study.
PMID:37439511Response assessment per RECIST criteria. Confirmed complete and partial responses were observed across schedules. Continued tolerability with low rates of dose-limiting toxicity. Cumulative fatigue possible.
PMID:34301750Durable disease control in responding patients, with six patients treated for over one year. Notably, no grade 3/4 thrombocytopenia was observed, reflecting a favorable hematologic safety profile.
PMID:34301750Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Idasanutlin
CautionBoth target MDM2-p53 pathway. Combining MDM2 inhibitors could cause excessive p53 activation and increased toxicity. Not recommended for co-administration.
Navtemadlin
CautionOverlapping MDM2 inhibition mechanism. Concurrent use may increase risk of hematologic toxicity. Clinical combination not studied.
Milademetan
CautionSimilar MDM2-targeting mechanism. Potential for additive toxicity if combined. No clinical data on co-administration.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Sulanemadlin
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.